The upcoming report from Eli Lilly (LLY) is expected to reveal quarterly earnings of $3.52 per share, indicating an increase of 36.4% compared to the year-ago period. Analysts forecast revenues of $12 ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

On Wednesday, U.S. stocks fell after Nvidia warned new restrictions on exports to China will cost it billions of dollars. The ...

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer ...

we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other key stocks that Jim Cramer highlights. In his latest appearance on CNBC’s Squawk on the Street ...

Eli Lilly LLY underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is selling ...

Goldman forecasts peak sales of $23.5 billion by 2035, well above the Street's projection of $16.8 billion, with initial data due in Q2 2025 and a global launch expected in 2026. Eli Lilly posted 32% ...